Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence, outcomes and predictors

Eric E. C. de Waal 1*, Bas van Zaane 1, Marnix M. van der Schoot 2, Albert Huisman 3, Faiz Ramjankhan 4, Wilton A. van Klei 1† and Nandor Marczin 5,6†

Abstract

Background: Vasoplegia after routine cardiac surgery is associated with severe postoperative complications and increased mortality. It is also prevalent in patients undergoing implantation of pulsatile flow left ventricular assist devices (LVAD). However, less is known regarding vasoplegia after implantation of newer generations of continuous flow LVADs (cfLVAD). We aim to report the incidence, impact on outcome and predictors of vasoplegia in these patients.

Methods: Adult patients scheduled for primary cfLVAD implantation were enrolled into a derivation cohort (n = 118, 2006–2013) and a temporal validation cohort (n = 73, 2014–2016). Vasoplegia was defined taking into consideration low mean arterial pressure and/or low systemic vascular resistance, preserved cardiac index and high vasopressor support. Vasoplegia was considered after bypass and the first 48 h of ICU stay lasting at least three consecutive hours. This concept of vasoplegia was compared to older definitions reported in the literature in terms of the incidence of postoperative vasoplegia and its association with adverse outcomes. Logistic regression was used to identify independent predictors. Their ability to discriminate patients with vasoplegia was quantified by the area under the receiver operating characteristic curve (AUC).

Results: The incidence of vasoplegia was 33.1% using the unified definition of vasoplegia. Vasoplegia was associated with increased ICU length-of-stay (10.5 [6.9–20.8] vs 6.1 [4.6–10.4] p = 0.002), increased ICU-mortality (OR 5.8, 95% CI 1.9–18.2) and one-year-mortality (OR 3.9, 95% CI 1.5–10.2), and a higher incidence of renal failure (OR 4.3, 95% CI 1.8–10.4). Multivariable analysis identified previous cardiothoracic surgery, preoperative dopamine administration, preoperative bilirubin levels and preoperative creatinine clearance as independent preoperative predictors of vasoplegia. The resultant prediction model exhibited a good discriminative ability (AUC 0.80, 95% CI 0.71–0.89, p < 0.01). Temporal validation resulted in an AUC of 0.74 (95% CI 0.61–0.87, p < 0.01).

Conclusions: In the era of the new generation of cfLVADs, vasoplegia remains a prevalent (33%) and critical condition with worse short-term outcomes and survival. We identified previous cardiothoracic surgery, preoperative treatment with dopamine, preoperative bilirubin levels and preoperative creatinine clearance as independent predictors.

Keywords: Cardiac Vasoplegia syndrome, Mechanical circulatory support, Incidence, Outcome, Morbidity, Mortality, Prediction
Background
Vasoplegia is characterized by severe hypotension due to lack in vasomotor tone refractory to catecholamine therapy. It occurs frequently after routine cardiac surgery (up to 27%) [1–6] and is associated with severe postoperative complications and increased mortality. Vasoplegia is even more prevalent after advanced surgical treatment of heart failure. The incidence of vasoplegia after heart transplantation (HTx) ranged between 8.8 and 54%, depending on the definition used [7–9], and 42% after pulsatile left ventricular assist device (pLVAD) implantation [10]. Less is known regarding vasoplegia after insertion of the newer generation of continuous flow LVADs (cfLVAD).

Published definitions for vasoplegia post-cardiac surgery vary markedly and include different hemodynamic parameters, vasoactive drugs, patient groups and variable observed time periods, which may lead to differences in reported incidences [1, 3, 8, 9, 11, 12] and associations with relevant clinical outcomes [1–6, 13]. Careful analysis of these definitions reveals that their application to the cfLVAD population is limited. Better identification of patients suffering from vasoplegia in this population and a better prediction of this critical condition might lead to improved optimization and result in improved outcomes. Therefore, for this specific patient population an appropriate and more unified definition taking into consideration high vasopressor requirements to maintain normal SVR and an extension of the time frame to the first 48 postoperative hours seems required.

As the newer generation of cfLVADs appears to improve postoperative survival [1–9, 14], we hypothesized that their implantation might be associated with a reduced incidence of vasoplegia, contributing to a better clinical course especially in the early postoperative period compared to older generations of LVADs, such as pLVADs. Based on these considerations, the first aim of the study was to uncover the incidence of vasoplegia using the unified definition and to compare this incidence to incidences obtained with three previously published definitions [1, 2, 9]. In addition, we set out to define the association of vasoplegia with several clinical outcomes including mortality, and to identify independent preoperative predictors of vasoplegia.

Methods
This study was performed in accordance with the declaration of Helsinki. Prior to data collection the study protocol was assessed by the institutional review board of the University Medical Centre Utrecht, The Netherlands and approved with an exemption from requiring ethical approval (14–053/C) because patients were not subjected to any investigational action.

Inclusion and exclusion criteria
We included patients > 18 years, suffering from slowly deteriorating chronic or acute (on chronic) heart failure, scheduled for short-term (Centrimag, St. Jude Medical, St. Paul, MN, USA) or long-term (Heartmate II or Heartmate III, St. Jude Medical, St. Paul, MN USA; or Heartware, HeartWare Inc., Framingham, MA, USA) cfLVAD implantation. As the study was focusing on first time cfLVAD implantation, we excluded patients with an already inserted assist device and patients with intraoperative right ventricular (RV) failure requiring a RV assist device implantation (RVAD) during the primary cfLVAD implantation procedure. A derivation cohort of patients operated in the period 2006–2013 was used for development of the prediction model, while this prediction model was temporally validated in a cohort of patients scheduled for cfLVAD implantation in our hospital in the period 2014–2016.

Data collection
Procedure related data were extracted from our anaesthesia information system (Anstat, Carepoint, Ede, The Netherlands), the electronic hospital information system (EZIS, ChipSoft, Amstderdam, The Netherlands) and the intensive care unit (ICU) data monitoring system (MetaVision, iMDsoft, Düsseldorf, Germany).

Definitions
In order to estimate the incidence of vasoplegia after cfLVAD implantation, we applied previously published definitions of vasoplegia [1–3, 8–11] (Table 1). As these definitions vary significantly in their hemodynamic criteria and included different postoperative time frames, we have attempted to simplify and unify these definitions by highlighting the common basic hemodynamic issue of low SVR and/or MAP in the setting of high vasopressor requirements (as used in the other definitions) with retention of a normal cardiac index (CI), covering the first 48 h after arrival in the ICU. Therefore, we constructed a unified definition and considered patients as vasoplegic if they had following conditions for at least three consecutive hours during the first 48 h after ICU arrival: a vasodilation criterion: MAP ≤ 50 mmHg or SVR ≤ 800 dynes·s·cm⁻²; a hemodynamic criterion: CI ≥ 2.5 l·min⁻¹·m⁻²; high vasopressor requirement: use of nor-epinephrine ≥ 200 ng·kg⁻¹·min⁻¹ or equivalent doses of vasopressors (epinephrine ≥ 200 ng·kg⁻¹·min⁻¹; dopamine ≥ 30 µg·kg⁻¹·min⁻¹; phentolamine ≥ 2 µg·kg⁻¹·min⁻¹, or vasopressin ≥ 0.08 U·min⁻¹) as proposed in the ATHOS-3 trial [15].

Thermal filament Continuous Cardiac output was measured with a pulmonary artery catheter (Type 744F75, Edwards Lifesciences, Irvine, California, USA) and a CI ≥ 2.5 l·min⁻¹·m⁻² was used in order to exclude...
other possible causes of hypotension and “vasoplegia”, such as right ventricular failure and hypovolemia.

To relate vasoplegia to doses of various administered vasoactive drugs, the Vasoactive Inotropic Score (VIS) [16] was calculated before the operation and during every hour in the first 48 postoperative hours: VIS = dopamine dose (μg·kg⁻¹·min⁻¹) + dobutamine dose (μg·kg⁻¹·min⁻¹) + 100 x epinephrine dose (μg·kg⁻¹·min⁻¹) + 10 x milrinone dose (μg·kg⁻¹·min⁻¹) + 10,000 x vasopressin dose (U·min⁻¹) + 100 x norepinephrine dose (μg·kg⁻¹·min⁻¹) + 10 x phenylephrine dose (μg·kg⁻¹·min⁻¹) [16]. Maximum VIS scores during the first and second 24 h after ICU arrival were used in the analysis.

Outcomes
For all used definitions, the primary endpoint was the incidence of vasoplegia after cfLVAD implantation, while secondary endpoints were renal failure [17], stroke [18], gastrointestinal bleeding, pneumonia, delirium and respiratory failure for bleeding or tamponade, ICU length of stay (ICU-LOS), ICU-mortality, Post-ICU-Hospital LOS; 30-days and 1-year mortality. Renal failure was defined as an abrupt (within 48 h) reduction in kidney function with an absolute increase in serum creatinine of more than or equal to 0.3 mg/dl (≥26.4 μmol/l), a percentage increase in serum creatinine ≥50% (1.5-fold baseline), or a reduction in urine output (documented oliguria of less than 0.5 ml/kg/hour for more than 6 h).

Statistical analysis
Statistical analysis was performed using SPSS version 24 for Mac (SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean ± standard deviation, or median [interquartile range]. Categorical variables are summarized as counts and percentages. All definitions were applied to estimate the incidence of postoperative vasoplegia and its association with outcomes after primary cfLVAD implantation. Univariable and multivariable logistic regression analyses were used to identify independent preoperative predictors of vasoplegia. A Cox-regression survival curve censored at cfLVAD removal for recovery, replacement or HTx was generated to explore a difference between both groups using the unified definition. For the unified vasoplegia definition, we used a cut-off p-value of 0.05 for inclusion of potential pre-operative predictors for the development of the final prediction model. Results are presented as odds ratio (OR) with 95% confidence interval (95%CI). The ability of predictors to discriminate patients with postoperative vasoplegia was quantified by calculating the area under the receiver operating characteristic curve of the predictor obtained from the multivariable regression model [19]. In addition, the obtained prediction model was temporally validated in a second cohort of patients operated on in the period 2014–2016 [20, 21].

Results
Demographic data, indication for cfLVAD implantation and medical history of 118 included patients in the derivation cohort are presented in Table 2.

Incidence of vasoplegia
The incidence of vasoplegia was 33.1% using the unified definition for the entire duration of our observation period. The Argenziano definition focuses on the early post bypass period and applying their criteria identified 28 patients (23.7%) as vasoplegic in our cohort and 9

### Table 1 Overview of definitions of vasoplegia used and their criteria

| Definition | Vasodilation criterion | Hemodynamic criterion | Vasopressor criterion | Preload criterion | Time moment/period |
|------------|------------------------|-----------------------|-----------------------|-------------------|-------------------|
| Argenziano [1] | MAP < 70 mmHg | CI > 2.5 l/min/m² | nor > 8 μg·min⁻¹ | | 5 min after CPB |
| Levin [2] | MAP < 50 mmHg and SVR < 800 dynes·cm⁻⁵ | CI > 2.5 l/min/m² | any vasopressor | CVP < 5 mmHg and PCWP < 10 mmHg | first 3 h after ICU arrival |
| Patarroyo [9] | SVR < 800 dynes·cm⁻⁵ | CI > 2.5 l/min/m² | ≥ 2 vasopressors: 1. epi > 4 μg·min⁻¹, 2. nor ≥4 μg·min⁻¹, 3. dopa ≥25 μg·kg⁻¹·min⁻¹, 4. vasopressin ≥1 U/hr | | 6–48 h after ICU arrival |
| Unified definition | MAP < 50 mmHg or SVR < 800 dynes·cm⁻⁵ | CI > 2.5 l/min/m² | nor > 200 ng·kg⁻¹·min⁻¹ or equivalent doses of other vasopressors: epi ≥ 200 ng·kg⁻¹·min⁻¹, dopa ≥10 μg·kg⁻¹·min⁻¹, phenyl ≥2 μg·kg⁻¹·min⁻¹, or vasopressin ≥0.08 U·min⁻¹ | | first 48 h after ICU arrival |
patients (7.6%) using our unified definition (Fig. 1a, b). Employing the Levin criteria for the first 3 postoperative ICU hours revealed only 3 patients as vasoplegic (2.5%) (Fig. 1a) while applying our proposed unified criteria for the same time frame revealed a higher number of 9 patients (7.6%). Closer analysis revealed that the discrepancy was related to CVP criteria as postoperative CVP levels remained high (> 8 mmHg) in our patient cohort despite cfLVAD therapy. If the CVP criteria were omitted from the Levin definition, we would have identified 10 patients (8.5%) as vasoplegic in this time period. Applying the Patarroyo definition for the 6–48 postoperative hours revealed 9 patients (7.6%) as vasoplegic (Fig. 1a) while using our proposed unified definition identified 36 patients (30.5%) being vasoplegic.

Since the existing definitions cover different perioperative periods, it is important to investigate if they capture the same patients (Fig. 1a). Only 2 patients were present in both the Argenziano and Levin groups and only 3 patients were common between the Argenziano and Patarroyo groups. There was no overlap between the Levin and the Patarroyo group. Sixteen patients met both the Argenziano and our proposed unified criteria. Our unified definition also captured all vasoplegic individuals identified by the Levin definition and 6 out of 9 vasoplegic patients by the Patarroyo definition.

As the unified definition covers the entire postoperative period, it is interesting to investigate the onset and the duration of early vasoplegia and the potential of late onset vasoplegia. Such analysis suggests that most patients presenting with vasoplegia immediately after cardiopulmonary bypass (CPB) (9 patients), remained vasoplegic for the early postoperative period in the ICU (8 patients up to 24 h and 4 patients up to 48 h). Furthermore, the onset, time frame and duration of vasoplegia appears different in these patients allowing identification of potential subgroups with unique pathophysiological patterns.

In addition, subgroup analysis using the unified definition revealed an incidence of vasoplegia of 52.6% (10 patients) in the short-term cfLVAD (Centrimag) group (19 patients) and a 29.3% (29 patients) incidence of vasoplegia in the long-term cfLVAD (Heartware-Heartmate II) group (99 patients).

### Association of vasoplegia with clinical outcomes
Vasoplegia was associated with higher risks of postoperative adverse events, such as renal failure, stroke, bleeding and mortality, regardless of the definition used (Additional file 1: Table S1). For instance, patients with vasoplegia using the Argenziano definition developed renal failure more often (OR 3.2, 95% CI 1.3–8.0) and showed a higher VIS on the first postoperative day (OR 1.0, 95% CI 1.0–1.0). There were no significant differences in outcome using the Levin definition. Vasoplegic patients according to the Patarroyo definition developed renal failure more often (OR 4.4, 95% CI 1.1–17.8), had increased requirements for continuous veno-venous hemofiltration CVVH (OR 7.3, 95% CI 1.8–30.0), and developed more often a stroke (OR 11.7, 95% CI 2.5–
53.3) and gastrointestinal bleeding (OR 5.0, 95% CI 1.1–22.9) during ICU stay. Moreover, the ICU mortality (OR 6.5, 95% CI 1.5–27.4) and 30-days mortality (OR 7.9, 95% CI 1.8–34.3) were higher in the vasoplegia group. Patients meeting the criteria of our unified definition of vasoplegia developed renal failure more often (OR 6.0, 95% CI 2.4–15.0), had increased requirements for CVVH (OR 7.9, 95% CI 2.6–23.6) and showed a higher VIS on the first and second postoperative day. They also required resternotomy for bleeding/tamponade more frequently in the first 48 postoperative hours (OR 3.0, 95% CI 1.2–7.8). Moreover, the ICU-LOS and the Post-ICU-Hospital-LOS were significantly longer. The crude ICU mortality (OR 5.8, 95% CI 1.9–18.2) and one-year mortality (OR 3.9, 95% CI 1.5–10.2) were higher in the vasoplegia group. Long-term patient survival after cLVAD implantation censored at device removal or HTx was significantly worse in patients with vasoplegia compared to no vasoplegia patients (Log-Rank p < 0.01) (Fig. 2a and b) and remained statistically significant when patients were stratified according to their Intermacs score (p < 0.01) (Fig. 2c1 and Fig. 2c2).

**Prediction model**

Univariable and multivariable logistic regression analysis of potential preoperative predictors for every definition of vasoplegia for the derivation cohort are reported in Table 3. Interestingly, only a few preoperative factors showed association with vasoplegia using the different existing vasoplegia definitions. Notably, we found no common preoperative predictors of vasoplegia using the older vasoplegia definitions, except previous cardiothoracic surgery and preoperative treatment with dopamine appearing as predictors of vasoplegia using the Patarroyo definition and our unified definition.

Using our unified definition, previous cardiothoracic surgery, preoperative treatment with dopamine, higher bilirubin and creatinine levels, a lower creatinine...
clearance and a higher Euroscore II remained significantly associated with a higher risk of postoperative vasoplegia in the multivariable analysis (Additional file 2: Table S2, Additional file 2: Table S3). Due to multicollinearity, Euroscore II (a prediction model based on some of the other predictors [22]) and creatinine were excluded from the multivariable regression. The remaining 4 factors were independent predictors. The risk to develop vasoplegia after primary cfLVAD implantation can be calculated using the following formula: Predicted

\[
\text{Predicted Risk} = a + bc_1 + c_2
\]

Fig. 2 Patient survival after cfLVAD implantation in all patients in the derivation cohort (Fig. 2a), in patients with and without vasoplegia in the derivation cohort (Fig. 2b) censoring at heart transplantation or device removal \((p < 0.01)\) and in patients with and without vasoplegia and stratified to Intermacs score (Fig. 2c)
| Table 3 | Independent predictors of vasoplegia using previous definitions of vasoplegia and the unified definition |
|--------|--------------------------------------------------------------------------------------------------|
| **Argenziano** |  |
| **Preoperative characteristics** | **No vasoplegia** | **Vasoplegia** | **P-value** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| Pre-op dobutamine | 43 (47.8%) | 19 (67.9%) | 0.04 | 2.65 (1.05–6.68) | 0.04 | 2.65 (1.05–6.68) | 0.04 |
| Pre-op VIS | 43 [0.0–7.3] | 65 [4.0–119] | 0.03 | 1.03 (1.00–1.06) | 0.05 |
| Neutrophil/ Lymphocyte –ratio | 4.5 [3.6–7.7] | 80 [5.6–9.5] | 0.04 | 1.13 (1.00 1.28) | 0.05 |
| **Levin** |  |
| **Preoperative characteristics** | **No vasoplegia** | **Vasoplegia** | **P-value** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| NCCMP | 3 (2.6%) | 2 (66.7%) | < 0.01 | 74.67 (5.22–1067.12) | < 0.01 | 1.00 |
| DCMP | 85 (73.9%) | 0 (0.0%) | < 0.01 | 0.0 (0.0–∞) | 1.00 |
| Clopidogrel | 6 (5.2%) | 1 (33.3%) | 0.04 | 9.08 (0.71–114.92) | 0.09 |
| Insuline | 4 (3.5%) | 1 (33.3%) | 0.01 | 13.88 (1.03–186.60) | < 0.05 |
| Preop norepinephrine | 12 (10.4%) | 3 (100%) | < 0.01 | 17.17 (1.45–203.67) | 0.02 |
| Lactate | 19 [1.4–2.7] | 13.1 | 0.03 | ∞ (0.00–∞) | 0.98 |
| **Patarroyo** |  |
| **Preoperative characteristics** | **No vasoplegia** | **Vasoplegia** | **P-value** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| Previous CT-surgery | 10 (9.2%) | 4 (44.4%) | < 0.01 | 7.92 (1.83–34.30) | < 0.01 | 10.4 (2.04–53.08) | < 0.01 |
| Pre-op dopamine | 22 (20.2%) | 5 (55.5%) | 0.02 | 4.94 (1.22–19.96) | 0.03 | 6.46 (1.36–30.55) | 0.02 |
| **Unified definition** |  |
| **Preoperative characteristics** | **No vasoplegia** | **Vasoplegia** | **P-value** | **OR (95% CI)** | **P-value** | **OR (95% CI)** | **P-value** |
| Previous CT-surgery | 5 (6.3%) | 9 (23.1%) | < 0.01 | 4.44 (1.38–14.34) | 0.01 | 7.60 (1.98–29.24) | < 0.01 |
| Euroscore II* | 206 [15.3–25.1] | 326 [20.6–422] | < 0.01 | 1.06 (1.03–1.10) | < 0.01 |
| Pre-op dopamine | 13 (16.5%) | 14 (35.9%) | 0.02 | 2.84 (1.17–6.88) | 0.02 | 3.83 (1.28–11.46) | 0.02 |
| Pre-op VIS | 4.1 [0.0–6.7] | 65 [4.0–106] | < 0.01 | 1.04 (1.00–1.08) | 0.06 |
| Bilirubin (μmol·l−1) | 270 [15.5–373] | 360 [25.0–445] | < 0.01 | 1.04 (1.01–1.07) | < 0.01 | 1.04 (1.01–2.08) | < 0.01 |
| Creatinine* (μmol·l−1) | 101 [91–150] | 157 [117–186] | 0.02 | 1.04 (1.01–1.02) | < 0.01 |
| Creatinine Clearance (ml·min−1) | 72 ± 29 | 57 ± 22 | < 0.01 | 0.97 (0.95–0.99) | < 0.01 | 0.97 (0.95–0.99) | < 0.01 |
probability = \frac{e^{\text{prediction score}}}{1 + e^{\text{prediction score}}} and the prediction score as follows: \ - 0.542 + 1.88 \times \text{previous cardiothoracic surgery} + 1.383 \times \text{preoperative use of dopamine} + 0.041 \times \text{preoperative total bilirubin} - 0.032 \times \text{creatinine clearance}. This final prediction model had a good discriminative ability (AUC = 0.80, 95\%CI 0.71–0.89, \ p < 0.01) (Fig. 3a). Using the Youden index, the best cut-off point for predicting vasoplegia was 0.34 (sensitivity 76.3\% and specificity 79.5\%).

The temporal validation dataset consisted of 73 patients scheduled for cLVAD implantation in our hospital in the period 2014–2016. Unfortunately, 1 patient died during the operation and data of 72 patients were available for further analysis. The incidence of vasoplegia in this validation cohort using the unified definition was 23.6\% (17 patients). The AUC of our final prediction model in this validation cohort was 0.74 (95\%CI 0.61–0.87, \ p < 0.01) (Fig. 3b).

Subgroup analysis of long-term cLVAD patients
The incidence of postoperative vasoplegia was 29.3\% if we only consider the long-term assist device patients in the derivation cohort. Significant differences between the vasoplegia and non-vasoplegia group were BMI, previous cardiothoracic surgery, preoperative Euroscore II, LMWH, use of dopamine, preoperative VIS-score, lymphocytes, bilirubin levels and creatinine clearance. Univariable and multivariable logistic regression analysis of potential preoperative predictors of vasoplegia (unified definition) in these long-term cLVAD group for the derivation cohort identified previous cardiothoracic surgery (OR 6.9, 95\% CI 1.70–28.25), LMWH (OR 0.08, 95\% CI 0.01–0.47) and preoperative use of dopamine (OR 6.21, 95\% CI 6.21–20.96) as independent predictors (AUC 0.78, 95\% CI 0.68–0.88).

Intraoperative factors associated with postoperative vasoplegia
Regarding the intraoperative period, patients with vasoplegia using the unified definition were more likely to be treated with dopamine (38.5\% vs. 19.0\%, \ p = 0.02) (Additional file 3: Table S4). Furthermore, factors related to previous cardiothoracic surgery, such as skin-to-skin time, use of units fresh frozen plasma, units of blood platelets and cell saver blood were significantly different between patients developing vasoplegia and those who did not develop vasoplegia (Additional file 4: Table S4).

Discussion
This study has comprehensively evaluated the most commonly used vasoplegia definitions and explored a new unified definition for the special conditions of cLVAD implantation. Using the unified definition, vasoplegia remains a prevalent (33\%) and clinically important condition, that was associated with important adverse clinical outcomes, such as renal failure, reinterventions, prolonged ICU-LOS, increased ICU mortality and a diminished survival over time. Previous cardiothoracic surgery, preoperative treatment with dopamine, preoperative bilirubin levels and preoperative creatinine
clearance appear as independent predictors of postoperative vasoplegia with a good discriminative ability.

**Justification of proposed definition**

To comprehensively address the issue of vasoplegia, we applied three previous definitions used in various fields of cardiac surgery [1, 2, 9]. We found that these definitions are based on different (cut-off values of) hemodynamic parameters at different time frames after surgery and consequently identified completely different patients as being vasoplegic. The definitions have major limitations in the setting of cfLVAD implantation. Argenziano’s definition used a liberal MAP threshold measured 5 min after weaning from CPB [1]. However, the immediate post-CPB period is characterized by rapid hemodynamic changes due to optimizing pump speed, changing ventricular geometry, adjusting inotropic support based on CO and RV function, and dynamic alterations in RV and LV preload following administration of fluids and/or blood products and protamine. The Levin’s criteria include the requirement for very low CVP < 5 mmHg. This is problematic in the end stage heart failure patients due to ventricular interdependence, biventricular failure, tricuspid regurgitation, and the clinical need of adequate RV preload to fulfill adequate preload of the cfLVAD. Specifically, our study shows that almost all cfLVAD patients exhibit higher CVPs at all stages during their ICU stay. Our conclusion therefore is that the Levin definition is not suitable for the special situation of cfLVAD implantation to define vasoplegia. Moreover, both Argenziano and Levin stratified patients using a single snap shot of clinical conditions excluding late onset vasoplegia in the ICU [1, 2]. In contrast, Patarroyo included less stringent hemodynamic values, more stringent vasoactive drug requirements, but excluded early onset vasoplegia [9].

For these crucial reasons, we developed and proposed a unified definition to capture vasoplegic patients in the full postoperative period after cfLVAD implantation. We aimed at capturing those patients who had very low MAP and/or low SVR (identical to Levin and Patarroyo [2, 9], but more stringent than Argenziano [1]) in the setting of normal cfLVAD flow, requiring higher vasoconstrictor treatment. On this point of vasoconstrictor treatment, our unified definition is more stringent than Argenziano and Levin, but less stringent than Patarroyo, who included at least two high dose vasoconstrictors.

**Incidence of vasoplegia after cfLVAD implantation**

According to our unified definition, one-third of the patients were vasoplegic. Applying the Argenziano definition to our study allowed direct comparison of early post bypass vasoplegia between the first generation LVAD implantation (Argenziano study) and the new generation of cfLVAD surgery (our current study). In such comparison, it appears that the insertion of the newer generation of cfLVADs is associated with a lower incidence of vasoplegia (24%) compared to vasoplegia after pLVAD implantation (42%) [1]. Moreover, it is remarkable that the incidence of vasoplegia after cfLVAD insertion is higher compared to the incidence of vasoplegia after routine cardiac surgery [1–6] and HTx [8, 9].

**Vasoplegia and postoperative outcomes**

While our study supports the recognition of improved outcomes after cfLVAD implantation compared to pLVADs [23, 24], it clearly demonstrates that vasoplegia and its sequelae are associated with postoperative outcomes representing an importantly increased risk for mortality. Moreover, nearly all ICU outcomes including renal failure, ICU stay, bleeding/tamponade were higher in vasoplegic patients (unified definition) compared to patients without vasoplegia. Thus, vasoplegia may be one of the most important determinants of the perioperative course and recovery in patients requiring mechanical circulatory support. The exact reasons and (molecular) mechanisms for such inferior outcomes of vasoplegia remain to be fully explored.

**Independent predictors of vasoplegia**

By analysing predictive factors for vasoplegia in patients specifically scheduled for cfLVAD implantation, our study represents a unique approach on the field. Recently, van Vessem and coworkers published their predictive models for vasoplegia, but they included a heterogeneous group of 225 patients with only 14% of their patients being LVAD recipients [12]. Using our unified definition, we observed that the occurrence of postoperative vasoplegia was independently related to previous cardiothoracic surgery, preoperative treatment with dopamine, preoperative bilirubin levels and preoperative creatinine clearance.

In literature, there are conflicting data on the influence of previous cardiothoracic surgery on the development of vasoplegia [3, 7]. Our observations are in line with Patarroyo [9], who identified previous cardiothoracic surgery as an independent predictor of vasoplegia. This might be related to more complex and longer surgery, increased perioperative bleeding and transfusion requirements, longer skin-to-skin times, and inflammatory response. A primed inflammatory state and imbalance of vasoactive mediators may explain our observations with the associated intraoperative factors. We found that the preoperative administration of dopamine is an independent predictor of postoperative vasoplegia. We can only speculate about the reason for this phenomenon. We think it may relate to the status of heart failure in that these patients suffer more severe forms of heart failure
Limitations

This is a retrospective study from a single institution with the usual limitations of such uncontrolled studies. Nevertheless, this design has allowed us to achieve our principle aim to highlight the incidence of vasoplegia and the impact on short-term outcome and survival. While we have undertaken a rigorous study and applied all major previous definitions of vasoplegia to the LVAD setting, we have realised these all have major shortcomings for the current application and needed to redefine vasoplegia for this setting. We believe that our concept unifies previous definitions and certainly identifies a very high-risk population, the unified definition needs to be agreed by wider international consensus and validated by prospective multicentre studies. In addition, the current study does not consider the perioperative metabolic or inflammatory profiles of our cfLVAD patients [30–32]. These important aspects will be investigated in the near future. Moreover, the study did not focus on specific types of cfLVAD. This is an interesting area but such investigation will require cooperation from different centres and will be subject of future plans. We also have limitations due to the sample size, as we were restricted to include only a limited number of variables in the multivariable analysis to predict postoperative vasoplegia [31]. Inotropic scores, such as the Vasoactive Inotropic Score should be used with caution, because several vasoactive drugs result in vasoconstriction and/or vasodilation, depending on the used doses and depending on the combination of used vasoactive agents. Moreover, the relative strength of action on the vasomotor tone of these vasoactive drugs compared to others is not fully understood. Finally, our focus was on prediction of vasoplegia using preoperative independent predictors. However, the incidence of vasoplegia might be influenced by associated inoperative factors, such as intraoperative transfusions [32], the use of CBP and the duration of CPB [3], as reported previously.

Conclusion

Previous definitions of vasoplegia all have limitations in their applicability to patients after cfLVAD implantation. Using our unified definition, vasoplegia affects about one-third of the patients after cfLVAD implantation. Despite successful surgery and cfLVAD performance, affected patients suffer more often from serious postoperative complications, such as prolonged ICU and hospital stay, increased renal failure, and markedly reduced survival. We identified previous cardiothoracic surgery, preoperative treatment with dopamine, preoperative bilirubin levels and preoperative creatinine clearance as independent preoperative predictors.

Additional files

**Additional file 1:** Table S1. Postoperative data of patients in the derivation cohort for every vasoplegia definition. Values are expressed as numbers (and %), or median (Interquartile range). CVVH = continuous veno-venous hemofiltration, Hb = Hemoglobin, ICU = intensive care unit, RV = right ventricular, RVAD = right ventricular assist device, VIS = vasoactive inotropic score. (DOCX 22 kb)

**Additional file 2:** Table S2. Preoperative medication in patients in the derivation and validation cohort. Values are expressed as numbers and % of patients, mean ± SD, or median (Interquartile Range). ACE-inhibitors = Angiotensin Converting Enzyme inhibitors; ARB = Angiotensin Receptor Blocker; IS = Inotropic Score; LMWH = Low Molecular Weight Heparin; VIS = Vasoactive Inotropic Score. (DOCX 18 kb)

**Additional file 3:** Table S3. Pre-op laboratory data in patients in the derivation and validation cohort. Values are expressed as mean ± SD or median (Interquartile Range). ALAT = Alanine Amino-Transferase, ASAT = Aspartate Amino-Transferase, BNP = Brain Natriuretic Peptide, CRP = C-reactive protein, Hb = Haemoglobin, RDW = Red Cell Distribution Width. (DOCX 16 kb)

**Additional file 4:** Table S4. Intraoperative data in patients in the derivation cohort. Values are expressed as numbers and % of patients, mean ± SD, or median (Interquartile range). CVVH = continuous veno-venous hemofiltration, Hb = Hemoglobin, ICU = intensive care unit, RV = right ventricular, RVAD = right ventricular assist device, VIS = vasoactive inotropic score. (DOCX 16 kb)
The authors declare that they have no competing interests.

Competing interests
Not applicable.

Because patients were not subjected to any investigational action. –

Approved with an exemption from requiring ethical approval (14 review board of the University Medical Centre Utrecht, The Netherlands and

Prior to data collection the study protocol was assessed by the institutional

This study was performed in accordance with the declaration of Helsinki.

All authors read and approved the final manuscript.

data interpretation, manuscript draft, and manuscript preparation; NM study

design, data collection, and manuscript preparation; WAvK data analysis,
data interpretation, manuscript draft, and manuscript preparation; NM study

design, data interpretation, manuscript draft, and manuscript preparation; All authors read and approved the final manuscript.

Ethics approval and consent to participate
This study was performed in accordance with the declaration of Helsinki. Prior to data collection the study protocol was assessed by the institutional review board of the University Medical Centre Utrecht, The Netherlands and approved with an exemption from requiring ethical approval (14–053/C) because patients were not subjected to any investigational action.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Anesthesiology, University Medical Centre Utrecht, Malistop Q04.2.317, Post Office Box 85500, 3508 GA Utrecht, Netherlands. 2Medical student, Faculty of Medicine, Utrecht University, Utrecht, The Netherlands.

Clinical chemist, Department of Clinical Chemistry and Hematology, University Medical Centre Utrecht, Utrecht, The Netherlands.

Anaesthesiologist, Section of Anaesthesia, Pain Medicine and Intensive Care, Imperial College, London, UK.

Department of Anaesthesia and Intensive Care, Semmelweis University, Budapest, Hungary.

Abbreviations
cFLVAD: Continuous flow left ventricular assist device; CI: Cardiac index; CPB: Cardiopulmonary bypass; CVP: Central venous pressure; CVVH: Continuous veno-venous hemofiltration; E2IS: Electronic hospital information system; HMIIRS: Heartmate II risk score; HTx: Heart transplantation; ICU: Intensive care unit; LOS: Length of stay; LVAD: Left ventricular assist device; MAP: Mean arterial pressure; OR: Odds ratio; pLVAD: Pulsatile left ventricular assist device; RV: Right ventricle; SVR: Systemic vascular resistance; VIS: Vaso-active inotropic score

Acknowledgements
The authors thank Hans van der Brugge, Wietze Pasma DVM and Frederiek de Heer MSc, for their assistance in data collection.

Funding
There was no external funding. The work was solely supported by departmental resources.

Availability of data and materials
The datasets used and analysed during the current study are available from the corresponding author on reasonable request and should remain within the confines of Dutch law regarding confidentiality.

Authors’ contributions
EECdW study design, data collection, data analysis, data interpretation, manuscript draft, and manuscript preparation; BvZ data analysis, data interpretation, manuscript draft, and manuscript preparation; MVMvdS data collection, data analysis, data interpretation, manuscript draft, and manuscript preparation; AH data collection, and approval of the final manuscript; FR patient recruitment, data collection, and manuscript preparation; WAvK data analysis, data interpretation, manuscript draft, and manuscript preparation; NM study design, data analysis, data interpretation, manuscript draft, and manuscript preparation. All authors read and approved the final manuscript.

Received: 20 July 2018 Accepted: 22 November 2018
Published online: 08 December 2018

References
1. Argenziano M, Chen JM, Choudri AF, Cullinane S, Garfein E, Weinberg AD, et al. Management of vasodilatory shock after cardiac surgery: identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg. 1998;116:973–80.
2. Levin RL, Degrange MA, Bruno GF, Del Mazo CD, Taborda DJ, Girotti JJ, et al. Methylene blue reduces mortality and morbidity in vasoplegic patients after cardiac surgery. Ann Thorac Surg. 2004;77:496–9.
3. Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with Vasoplegic syndrome. Circulation. 2009;120:1664–71.
4. Papadopoulos G, Sintou E, Siminelakis S, Koletis E, Baikousis NG, Apostolakis E. Perioperative infusion of low-dose of vasopressin for prevention and management of vasodilatory vasoplegic syndrome in patients undergoing coronary artery bypass grafting-a double-blind randomized study. J Cardiothorac Surg. 2010;5:17.
5. Carrel T, Englberger L, Mohacsi P, Neidhart P, Schmidli J. Low systemic vascular resistance after cardiopulmonary bypass: incidence, etiology, and clinical importance. J Card Surg. 2000;15:347–53.
6. Wels F, Kiger E, Beiras-Fernandez A, Nassau K, Reuter D, Goetz A, et al. Association between vasopressor dependence and early outcome in patients after cardiac surgery. Anaesthesia. 2006;61:938–42.
7. Chemmalakuzhy J, Costanzo MR, Meyer P, Piccione W, Kao W, Winkle E, et al. Hypotension, acidosis, and vasodilatation syndrome post-heart transplant: prognostic variables and outcomes. J Heart Lung Transplant. 2001;20:1075–83.
8. Byrne J. Risk factors and outcomes for “vasoplegia syndrome” following cardiac transplantation. Eur J Cardiothorac Surg. 2004;25:327–32.
9. Paratonyo M, Simbaqueba C, Sherestsia K, Starling RC, Smedira N, Tang WHW, et al. Pre-operative risk factors and clinical outcomes associated with vasoplegia in recipients of orthotopic heart transplantation in the contemporary era. J Heart Lung Transplant. 2012;31:282–7.
10. Argenziano M, Choudri AF, Oz MC, Rose EA, Smith CR Jr, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation; 1997;86: Nov pp. 2888–2901.
11. Sun X, Zhang L, Hill PC, Lowery R, Lee AT, Molynieux RE, et al. Is incidence of postoperative vasoplegic syndrome different between cPump and on-pump coronary artery bypass grafting surgery? Eur J Cardiothorac Surg. 2008;34:820–5.
12. van Vessem ME, Palmen M, Couperus LE, Mertens B, Berendsen RR, Tops LF, et al. Incidence and predictors of vasoplegia after heart failure surgery. Eur J Cardiothorac Surg. 2017;51:532–8.
13. Omar S, Ahmed Z, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sciences. 2017;349:80–8.
14. Allen SJ, Sidebotham D. Postoperative care and complications after ventricular assist device implantation. Best Pract Res Clin Anaesthesiol. 2012;26:231–46.
15. Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, et al. Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc. 2017;19:43–9.
16. Nguyen HV, Havalad V, Aponte-Patel L, Murata AT, Wang DY, Rusano V, et al. Temporary biventricular pacing decreases the vasoactive-inotropic score after cardiac surgery: a substudy of a randomized clinical trial. J Thorac Cardiovasc Surg. 2013;146:296–301.
17. Mehta RL, Kellum JA, Shah SV, Moltitordi BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11:183.
18. New PW, Buchbinder R. Critical appraisal and review of the Rankin scale and its derivatives. Neuroepidemiology. 2006;26:4–15.
19. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–43.
20. Steyerberg EW, Harrell FE, Bonsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol. 2001;54:774–81.
21. Steyerberg EW, Bleeker SE, Molli HA, Grobbe DE, Moons KGM. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol. 2003;56:441–7.
22. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012;41:734–44 discussion 744–5.
23. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. New Engl J Med. 2001;345:1435–43.
24. Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant. 2014;33:555–64.
25. Lavigne D. Vasopressin and methylene blue: alternate therapies in vasodilatory shock. Sem CardiothoracVasc Anesth. 2010;14:186–9.
26. Yu C, Chen J, Guan W, Han Y, Wang WE, Wang X, et al. Activation of the D4 dopamine receptor attenuates proliferation and migration of vascular smooth muscle cells through downregulation of AT1a receptor expression. Hypertens Res. 2015;38:588–96.
27. Moller S, Henriksen JH. Cardiopulmonary complications in chronic liver disease. World J Gastroenterol. 2006;12:526–38.
28. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. Hepatology. 1994;20:1359–63.
29. Masai T, Sawa Y, Ohtake S, Nishida T, Nishimura M, Fukushima N, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hep; 38: 588-atic microcirculation. Ann Thorac Surg. 2002;73:549–55.
30. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992;42:1020–9.
31. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373–9.
32. Alfirevic A, Xu M, Johnston D, Figueroa P, Koch CG. Transfusion increases the risk for vasoplegia after cardiac operations. Ann Thorac Surg. 2011;92:812–9.